Quince Therapeutics director Philip Low resigns from Board

Quince Therapeutics, Inc.

Director Philip Low, Ph.D. resigned from the Board effective March 27, 2023.
Departure was not a result of any disagreement with the Company, Board, or management.
No replacement has been announced for the vacant Board seat.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Philip Low

Director

QNCX · Quince Therapeutics, Inc.

Effective: 2023-03-27
Filed: March 28, 2023, 7:59 PM ET

On March 27, 2023, Philip Low. Ph.D., a member of the Board of Directors (the “Board”) of Quince Therapeutics, Inc. (the “Company”), tendered his resignation from the Board, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Philip Low resigned as Director at Quince Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On March 27, 2023, Philip Low. Ph.D., a member of the Board of Directors (the “Board”) of Quince Therapeutics, Inc. (the “Company”), tendered his resignation from the Board, effective immediately

View on SEC.gov

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-082305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.